banner
You are not using a standards compliant browser. Because of this you may notice minor glitches in the rendering of this page. Please upgrade to a compliant browser for optimal viewing:
Firefox
Internet Explorer 7
Safari (Mac and PC)
Press Release
Virus attacks childhood cancers
Monday, August 29, 2011


Vesicular stomatitis virus (VSV)

Researchers from Yale University are looking to a virus from the same family as the rabies virus to fight a form of cancer primarily found in children and young adults. They report their findings in the September 2011 issue of the Journal of Virology.

Soft tissue sarcomas are cancers that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons, fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue. While relatively rare in adults, they represent approximately 15% of pediatric malignancies and result in death for approximately one-third of patients within 5 years of diagnosis.

Vesicular stomatitis virus (VSV) is a rhabdovirus, which is the same family of viruses as rabies, and causes a disease similar to foot and mouth disease in cattle. Recent research has discovered that this virus also is oncolytic, meaning it seeks out and destroys cancerous tumors. Previous studies have already shown VSV to be promising in treating brain tumors in mice.

In this study the researchers investigated the potential of VSV and an oncolytically enhanced version of the virus (VSV-rp30a) to effectively target and kill 13 different sarcomas. Both of the viruses efficiently infected and killed 12 of the sarcomas. The resistance of the one surviving sarcoma line was eventually overcome by pretreatment with compounds that antagonize interferon signaling.

Additionally they looked at the ability of VSV-rp30a to infect and arrest tumor growth in mice.

"A single intravenous injection of VSV-rp30a selectively infected all subcutaneous human sarcomas tested in mice and arrested the growth of tumors that otherwise grew 11-fold," say the researchers. "Overall, we find that the potential efficacy of VSV as an oncolytic agent extends to nonhematologic mesodermal tumors and that unusually strong resistance to VSV oncolysis can be overcome with interferon attenuators."

###

American Society for Microbiology: http://www.asm.org



Thanks to American Society for Microbiology for this article.

This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.



This press release has been viewed 88 time(s).

Comments
No comments recorded.
Add Comment?

For youtube videos, paste embed code directly in the text box

-

Members do not need to provide an address

-
Rate Article
Total votes: 0
Select Comment Validation Method
Member
Name/URL (Guest)
FaceBook (Guest)
Member Commenting:


Authenticate with Facebook before submitting

OR


Make your LabSpaces comments count. Start earning LabSpaces points by becoming a member! Learn more.
Please verify that you are human: Register for LabSpaces
Make your LabSpaces comments count. Start earning LabSpaces points by becoming a member! Learn more.


Please authenticate before trying to post a comment.

If you would like to remain anonymous, please enter a new name and link below


Friends